Riskpilot← Back to searchSign inGet full accessKILEN APOTEK AS
ASActiveOrg 987011912Kilgata 25, 3217 SandefjordRetail sale of pharmaceutical products · NACE 4773Est. 20040 employeeswww.kilenapotek.no
Revenue 2024
NOK 28,7M
+5% vs 2023
EBITDA margin
-0.6%
-168% vs 2023
Equity ratio
-22.3%
Financial strength
Net profit 2024
NOK -453K
-62% vs 2023
| Revenue | NOK 28,7M | +5% |
| EBITDA | NOK -177K | -168% |
| Net profit | NOK -453K | -62% |
| Total assets | NOK 11,8M | +50% |
| Equity | NOK -2,6M | +24% |
| Employees | 0 | — |
Legal name
KILEN APOTEK AS
Org number
987011912
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
31. juli 2004
Share capital
NOK 255 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap, styrets leder alene eller daglig leder alene.
Company purpose
Apotekvirksomhet.
Address
Kilgata 25, 3217 Sandefjord
Website
www.kilenapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 24 910 | 25 350 | 24 068 | 27 360 | 28 730 |
| Staff expenses | −4 654 | −4 307 | −4 083 | −4 112 | −4 358 |
| EBITDA | −85 | −171 | −210 | 259 | −177 |
| Depreciation & amort. | −241 | −242 | −242 | −242 | −241 |
| EBIT | −326 | −414 | −452 | 17 | −419 |
| Net financials | −115 | −376 | −339 | −375 | −163 |
| Profit before tax | −441 | −790 | −791 | −358 | −581 |
| Tax | −97 | −174 | −174 | −79 | −128 |
| Net profit | −344 | −616 | −617 | −279 | −453 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 306 | 6 395 | 6 212 | 7 857 | 11 760 |
| Equity | −2 224 | −2 840 | −3 457 | −3 457 | −2 623 |
| Long-term debt | 274 | 83 | 0 | 2 675 | 2 194 |
| Short-term debt | 9 256 | 9 153 | 9 669 | 8 639 | 12 189 |
| Total debt | 9 530 | 9 236 | 9 669 | 11 314 | 14 383 |
EBITDA margin
-0.6%
This company
15.8%
Market median
-104% vs market
20202024
Equity ratio
-22.3%
This company
38.2%
Market median
-158% vs market
20202024
Return on equity
-45346100.0%
This company
18.4%
Market median
-246446296% vs market
20202024
Net profit margin
-1.6%
This company
8.1%
Market median
-120% vs market
20202024
Asset turnover
2.44×
This company
1.12×
Market median
+118% vs market
20202024
Debt / equity
5.48×
This company
0.62×
Market median
-784% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
KK Chief Executive Officer | Chief Executive Officer | 2023 |
GO Deputy Member | Deputy Member | 2013 |
AA Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 90.11% | 90.11% | 2024 | |
| Individual | 15.5% | 15.5% | 2022 | |
| Individual | 6.73% | 6.73% | 2024 | |
| Individual | 1.78% | 1.78% | 2024 | |
| Individual | 1.38% | 1.38% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KILEN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kari Kyrkjebø Dreng | Chief Executive Officer | 0 companies |
| Garm Oscar Lyckander | Deputy Member | 0 companies |
| Abrar Ahmad | Chief Executive Officer | 0 companies |
| Bror-Lennart Mentzoni | Chairman | 0 companies |